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Background: Animal studies have shown that zinc intake has protective effects against type 2 diabetes, but few
studies have been conducted to examine this relationship in humans. The aim of this study is to investigate if
dietary zinc is associated with risk of type 2 diabetes in a longitudinal study of mid-age Australian women.
Methods: Data were collected from a cohort of women aged 45-50 years at baseline, participating in the Australian
Longitudinal Study on Women’s Health. A validated food frequency questionnaire was used to assess dietary intake
and other nutrients. Predictors of 6-year incidence of type 2 diabetes were examined using multivariable logistic
regression.
Results: From 8921 participants, 333 incident cases of type 2 diabetes were identified over 6 years of follow-up.
After adjustment for dietary and non-dietary factors, the highest quintile dietary zinc intake had almost half the
odds of developing type 2 diabetes (OR = 0.50, 95% C.I. 0.32–0.77) compared with the lowest quintile. Similar
findings were observed for the zinc/iron ratio; the highest quintile had half the odds of developing type 2 diabetes
(OR = 0.50, 95% C.I 0.30-0.83) after multivariable adjustment of covariates.
Conclusions: Higher total dietary zinc intake and high zinc/iron ratio are associated with lower risk of type 2
diabetes in women. This finding is a positive step towards further research to determine if zinc supplementation
may reduce the risk of developing type 2 diabetes.
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Diabetes, a disorder of metabolism results in substantial
morbidity and mortality, primarily from macrovascular
(myocardial infarction, stroke, and peripheral vascular
disease), and microvascular effects (retinopathy, nephro-
pathy, and neuropathy). The World Health Organization
(WHO) estimated that 3.4 million people worldwide died
from consequences of high fasting blood sugar in 2010
[1]. Currently 347 million adults worldwide have diabetes;
the prevalence is continuing to rise and is expected to be
the 7th leading cause of death by 2030 [1]. This will have* Correspondence: Khanrin.vashum@newcastle.edu.au
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reproduction in any medium, provided the orthe greatest impact on the productive population of coun-
tries, as people under the age of 70 years constitute almost
half of all diabetic deaths.
Molecular and cellular studies have demonstrated that
the mineral zinc plays a key role in the synthesis and
action of insulin under normal physiological conditions
and in type 2 diabetes (T2D). Observational studies have
reported an association between reduced serum zinc and
established T2D [2]. Protective effects of zinc supplemen-
tation have also been demonstrated in rodent models of
T2D [3], but this has not been properly tested in humans.
Epidemiological studies have observed an association
between reduced zinc status and T2D [4,5]. This asso-
ciation may simply be due to loss of zinc through the
kidneys due to diabetic nephropathy; indeed, a number
of studies have shown that urinary excretion of zinc isl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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compared with controls [5]. A study by Marreiro et al
found that 35.5% of study subjects with T2D had higher
urinary zinc excretion than normal [6]. However, other
lines of evidence support a more direct causative role of
zinc in the pathogenesis of T2D. A few studies have exa-
mined the effect of zinc supplementation in T2D patients
with many showing an improvement in glycaemic control
[7-9]. Only one study has examined the use of zinc sup-
plementation for the primary prevention of T2D [6]. This
study was identified and the only study included in a
recent Cochrane review that examined the role of zinc
supplementation for the primary prevention of T2D and
found that there was insufficient evidence to suggest the
use of zinc supplementation in the prevention of T2D
[10]. Recent support for the use of zinc supplementation
for reducing the risk of T2D comes from the Nurses’
Health Study (n ~ 82,000) where higher dietary zinc intake
was associated with a lower risk of developing T2D in
women [11]. However, another study in a Chinese popu-
lation did not find an association between dietary zinc
intake and hyperglycaemia but did find an association
with the dietary zinc to haeme iron ratio [12]. In light of
these findings we have used a large population-based
cohort of women to examine these associations in an
Australian context. In addition, this study also examines
dietary zinc to iron ratio as iron is known to interact with
the absorption of zinc and a recent study showed that zinc
to haeme iron ratio was inversely associated with risk of
diabetes in US women [11].
Methods
The Australian longitudinal study on women’s health
The Australian Longitudinal Study on Women’s Health
(ALSWH) is a prospective study examining the health and
wellbeing of three cohorts of women aged 18–23 years
(young), 45–50 years (mid-aged), and 70–75 years (older)
at the time of the initial surveys in 1996. Women were se-
lected randomly within each age group from the National
Medicare Health Insurance Database (which includes all
permanent residents of Australia regardless of age, inclu-
ding immigrants and refugees) with intentional overre-
presentation of women living in rural and remote areas,
which was achieved by sampling women in these areas at
twice the rate of women in urban areas. Further details of
the recruitment methods and response rates have been
described elsewhere [13]. The study collects self-reported
data using mailed surveys at 2- to 3-year intervals from
40,000 women living in all states and territories of
Australia. The surveys include questions about health
conditions, symptoms, and diagnoses; use of health ser-
vices; health-related quality of life; social circumstances,
including work and time use; demographic factors; and
health behaviours. Complete details of each survey (S) areon the study website (available at http://www.alswh.org.au).
Informed written consent was obtained from all parti-
cipants in 1996, with ethical clearance for the study
obtained from the University of Newcastle. Ethics com-
mittees at the Universities of Newcastle and Queensland
approved the ALSWH. This article only includes data
from the mid-aged cohort as this age group (45-50 years)
were at higher risk of developing diabetes than the other
two cohorts (18–23 and 70–75 years) of women and were
the only age group with food frequency questionnaire
(FFQ) data collected. There were five waves of data collec-
tion from 1996 to 2007 (S1, 1996; S2, 1998; S3, 2001; S4,
2004; and S5, 2007). Surveys 1, 2 and 3 consisted of
13716, 12338, and 11228 women respectively. The res-
ponse rate for S3 of the mid age cohort was 83% of
women who had completed S1 and had not died (n-115)
or become too ill to complete further surveys (n = 21).
Other non-respondents included those who were unable
to be contacted (n = 930), were contacted but did not
complete the survey (n = 998), and those who withdrew
from the project (n = 242) [13]. Of the women who com-
pleted S3 (then aged 50–55 years), 11196 completed the
food frequency questionnaire (FFQ) and 8921 participants
remained in the study and were available for analysis by
S5. Those who were lost to follow-up were not signifi-
cantly different but were more likely to be born outside
Australia, less educated, or a current smoker.
Dietary assessment
At S3, dietary intake was assessed using an FFQ known as
the Dietary Questionnaire for Epidemiological Studies
(DQES) Version 2. Both the development of the question-
naire [14] and its validation in mid-aged Australian
women has been previously reported [15]. This question-
naire asks respondents to report their usual consumption
of 74 foods and six alcoholic beverages over the preceding
12 months using a 10-point frequency scale. Additional
questions are asked about the number of serves or type of
fruit, vegetables, bread, dairy products, eggs, fat spreads
and sugar and further details are provided in Hodge et al.
[15]. Nutrient intakes were computed from NUTTAB
1995, a national government food composition database
of Australian foods NUTTAB95 [16], using software
developed by the Cancer Council of Victoria. The vali-
dation of the FFQ against a 7-day weighted food record
showed Pearson correlation coefficient = 0.4 for dietary
zinc intake. The FFQ validation study deemed the cor-
relation coefficient acceptable as it is of similar magnitude
to those previously reported [15].
Ascertainment of type 2 diabetes
At each survey women were asked if a doctor had told
them that they had T2D. At S1 they were asked if they
had ever had a diagnosis of T2D. At S2, S3, S4, and S5
Vashum et al. BMC Endocrine Disorders 2013, 13:40 Page 3 of 8
http://www.biomedcentral.com/1472-6823/13/40they were asked whether they had been diagnosed with
T2D in the time period that had elapsed since the pre-
vious survey. Prevalence of T2D at each survey was
defined as the proportion of these women who reported
at that survey or a previous survey that they had been
told they had T2D.
Measurement of non-dietary factors
Social and behavioural factors were based on information
collected at S3 (AIHW 2001). Participants were asked to
report frequency of engaging in vigorous (e.g., aerobics,
jogging) and less vigorous (e.g., walking and swimming)
exercise lasting for <20 min in a normal week. Responses
were scored using approximate weekly frequencies of
exercise (never = 0, once a week = 1, 2 or 3 times per
week = 2.5, 4–6 times per week =5, every day = 7, and
more than once a day = 10) and then weighted to reflect
the intensity of the activity (vigorous = 5 and less vigo-
rous = 3). The resulting physical activity scores ranged
from 0 to 80 and were categorized as “nil/sedentary
(<5),” “low (5 to 15),” “moderate (16 to 25),” or “high
(>25).” A score of 15 is commensurate with the current
recommendation of moderate intensity activity on most
days of the week. This measure is described in more detail
elsewhere [17] and has previously been shown to have
acceptable test-retest reliability [18]. Standard questions
were used to categorize respondents as never-smoker, ex-
smoker, or current smoker; the latter was grouped as
smoking less than 10 cigarettes (c) per day (<10c/d),
10-19 c/d and > =20 c/d.
Body mass index (BMI) was calculated as self-reported
weight (kg) divided by the square of estimated height
(m2). Medical history of arthritis, congestive heart disease
(CHD), stroke, hypertension (HT), asthma and depression
along with use of hormone replacement therapy (HRT)
(coded as either yes or no) were all self-reported. The par-
ticipants were also asked to report the number of supple-
ments being used and categorised as taking multivitamin
& mineral supplements (yes or no).
Statistical analysis
Chi square test was used to compare differences in cate-
gorical variables, and ANOVA was used to compare
mean values of continuous variables between groups.
Predictors of 6-year incidence of T2D were examined
using forward stepwise multivariable logistic regression
in stepped approach, with the main predictor being
energy adjusted zinc and zinc/iron ratio measured at S3
used to predict incidence of T2D by S5. Women who
first reported a diagnosis of T2D at S1, S2, or S3 (preva-
lent cases) were excluded from this analysis (N= 567).
The macronutrient variables are adjusted for total energy
intake by calculating their component of total energy
(as a%). The micronutrients were adjusted for totalenergy by regressing (using linear regression) the natural
log of the micronutrient on the natural log of total
energy and extracting the standardized residuals.
The multivariable analysis controlled for dietary factors
(energy adjusted fibre, fat and iron) and non-dietary fac-
tors (BMI, smoking status, HRT, exercise group, history
(yes/no) of arthritis, CHD, HT, asthma and depression).
P values for trends were conducted by treating quintile of
energy-adjusted zinc as a continuous variable. Statistical
significance was considered when 2 sided p < 0.05. STATA
software version 11 was used for all statistical analyses.
Results
At the end of the 6 years follow-up 333 incident cases of
T2D were identified out of 8,921 participants. Table 1
describes characteristics of participants at survey 3 by
quintile of energy-adjusted zinc. Dietary zinc intake was
divided into quintiles of energy-adjusted zinc with quin-
tile 1 as the lowest intake and quintile 5 the highest
intake. The dietary zinc intake of the lowest and highest
quintile was 5.94 mg (95% CI 5.90 -5.99) and 17.35 mg
(95% CI 17.12-17.59) respectively and the mean intake
was 10.66 mg/day. At baseline (Table 1) non-dietary
factors found to be significantly different across quintiles
included smoking status, exercise, BMI, HRT, HT, asthma
and depression. Energy-adjusted dietary factors found to
be significantly different across quintiles includes carbohy-
drates, total protein, total fat (including cholesterol and
saturated, polyunsaturated, monounsaturated fat), dietary
fibre, minerals (iron, calcium, magnesium, sodium and
potassium) and vitamins, which includes retinol, vitamin
C and E. Those in the highest quintile of intake were more
likely to smoke greater than 20 cigarettes per day and have
a history of hypertension. Women in the lower quintiles
were found to have a more sedentary life with nil or little
exercise but interestingly those with higher intake of zinc
also had higher BMI. Of particular interest in this investi-
gation, those in the highest quintile of zinc intake also had
the highest intake of dietary iron. The most commonly
recorded dietary source of zinc was meat, fish and poultry
as the major contributors, though cereals and dairy pro-
ducts were also a substantial source.
Table 2 shows the median value, along with the mini-
mum and maximum values of energy-adjusted zinc for
each quintile of dietary zinc. These values represent the
standardized residuals after adjusting for total energy in-
take. For example, the median values of energy-adjusted
zinc in Q1 and Q5 are -1.25 and 1.24 respectively indi-
cating that the middle value for energy-adjusted zinc in
Q5 is much higher than that of Q1. In an age adjusted
analysis there was no significant association across quin-
tiles between energy-adjusted zinc and risk of T2D
(Table 2). After adjustment for non-dietary factors in-
cluding age, BMI, smoking, HRT, exercise group, history
Table 1 Characteristics of subjects at survey 3 by quintile of energy-adjusted zinc
Quintile of energy-adjusted zinc
Characteristic Sub group/or mean(Std) Q1 Lowest (n = 1785) Q3 Middle (n = 1784) Q5 Highest (n = 1784) p-value
Smoking status Never smoker 948 (53%) 1033 (58%) 922 (52%) <0.001
Former smoker 568 (32%) 531 (30%) 569 (32%)
smoker < 10 c/d 84 (4.7%) 75 (4.2%) 76 (4.3%)
smoker 10-19 c/d 77 (4.3%) 64 (3.6%) 81 (4.6%)
smoker > = 20 c/d 100 (5.6%) 76 (4.3%) 130 (7.3%)
Exercise group Nil/sedentary 321 (19%) 271 (16%) 323 (19%) 0.003
Low 621 (37%) 683 (40%) 622 (36%)
Moderate 318 (19%) 355 (21%) 338 (20%)
High 437 (26%) 408 (24%) 433 (25%)
Hormone replacement therapy No 1250 (70%) 1193 (67%) 1160 (65%) 0.020
Yes 535 (30%) 591 (33%) 624 (35%)
Heart disease No 1743 (99%) 1741 (98%) 1735 (98%) 0.077
Yes 26 (1.5%) 28 (1.6%) 30 (1.7%)
Hypertension No 1498 (85%) 1495 (85%) 1449 (82%) 0.038
Yes 271 (15%) 274 (15%) 316 (18%)
Arthritis No 1409 (80%) 1358 (77%) 1375 (78%) 0.342
Yes 360 (20%) 411 (23%) 390 (22%)
Asthma No 1568 (89%) 1602 (91%) 1584 (90%) 0.038
Yes 201 (11%) 167 (9.4%) 181 (10%)
Depression No 1538 (87%) 1605 (91%) 1597 (90%) 0.001
Yes 231 (13%) 164 (9.3%) 168 (9.5%)
Age mean (SD) 52.6 (1.4) 52.6 (1.5) 52.4 (1.5) 0.004
Body mass index mean (SD) 26.0 (5.4) 26.5 (5.1) 27.2 (5.4) <0.001
Total energy intake mean (SD) 6676 (2415) 6604 (2275) 6687 (2790) 0.508
Alcohol intake mean (SD) 6.2 (11.0) 8.3 (12.1) 9.7 (14.9) <0.001
Number of supplements mean (SD) 1.1 (1.1) 1.1 (1.1) 1.0 (1.1) 0.163
Carbohydrates (% of energy) mean (SD) 48.2 (5.8) 45.6 (5.8) 41.0 (7.5) <0.001
Dietary fibre (% of energy) mean (SD) 2.4 (0.7) 2.5 (0.6) 2.5 (0.8) <0.001
Total protein (% of energy) mean (SD) 17.1 (2.1) 20.8 (1.7) 25.1 (2.8) <0.001
Total fat (% of energy) mean (SD) 35.5 (5.5) 34.3 (5.9) 34.5 (6.6) <0.001
Saturated fat (energy adjusted) mean (SD) 14.0 (3.8) 13.5 (3.4) 13.9 (3.3) <0.001
Polyunsaturated fat (% of energy) mean (SD) 6.3 (2.3) 5.5 (1.9) 4.7 (1.5) <0.001
Monounsaturated fat (% of energy) mean (SD) 12.1 (2.2) 12.1 (2.4) 12.6 (2.8) <0.001
Iron (energy adjusted) mean (SD) −0.605 (0.984) 0.022 (0.905) 0.543 (0.897) <0.001
Cholesterol (energy adjusted) mean (SD) −0.584 (1.170) −0.043 (0.827) 0.607 (0.855) <0.001
Retinol (energy adjusted) mean (SD) 0.451 (0.947) 0.030 (0.932) −0.525 (0.993) <0.001
Vitamin C (energy adjusted) mean (SD) −0.092 (1.198) 0.024 (0.957) 0.028 (0.895) 0.001
Vitamin E (energy adjusted) mean (SD) 0.346 (1.094) 0.035 (0.923) −0.407 (0.939) <0.001
Calcium (energy adjusted) mean (SD) −0.374 (0.901) 0.126 (0.940) 0.089 (1.166) <0.001
Magnesium (energy adjusted) mean (SD) −0.453 (1.001) 0.064 (0.901) 0.268 (1.069) <0.001
Sodium (energy adjusted) mean (SD) −0.432 (1.030) 0.026 (0.930) 0.345 (0.999) <0.001
Potassium (energy adjusted) mean (SD) −0.594 (1.072) 0.067 (0.891) 0.454 (0.915) <0.001
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Table 2 Stepwise approach to examine energy-adjusted zinc as an independent predictor of a new diagnosis of
diabetes
Quintile of energy-adjusted zinc
Q1 Q2 Q3 Q4 Q5 P
Number of women 1785 1784 1784 1784 1784
Energy-adjusted zinc [median (min, max)] −1.25
(-4.8, -0.79)
−0.48
(-0.79, -0.23)
0.01
(-0.23, 0.26)
0.50
(0.26, 0.79)
1.24
(0.79, 4.45)
Number of diabetics 80 60 59 74 60
Odds ratio
• Age adjusted 1.00 0.74
(0.53 to 1.05)
0.73
(0.52 to 1.03)
0.99
(0.67 to 1.28)
0.75
(0.53 to 1.05)
0.319
• Age & non-dietary† factors adjusted 1.00 1.00 0.82
(0.56 to 1.19)
0.65
(0.44 to 0.96)
0.83
(0.58 to 1.19)
0.56
(0.38 to 0.83)
0.010
• Age, non-dietary† and dietary‡ factors adjusted 1.00 0.78
(0.53 to 1.15)
0.60
(0.40 to 0.91)
0.77
(0.52 to 1.13)
0.48
(0.31 to 0.75)
0.004
• Age, non-dietary† and dietary‡ factors adjusted plus alcohol
intake and use of supplements
0.80
(0.54 to 1.17)
0.60
(0.40 to 0.90)
0.78
(0.53 to 1.15)
0.50
(0.32 to 0.77)
0.006
† Non-dietary factors were BMI; smoking status; HRT; exercise group; and history of arthritis, CHD, hypertension, asthma and depression.
‡ Dietary factors were energy-adjusted fiber, iron and fat.
Adjustment for family income in the models resulted in a loss of 1300 observations but the p-values for the test for trend were very similar (p = 0.010 for all 3
adjusted models).
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decrease in the odds of developing T2D across the quin-
tiles was observed, which was statistically significant
(p = 0.010). Further adjustment for dietary factors (energy
adjusted fibre, iron and fat) strengthened the association
(p = 0.004). Additional adjustment for alcohol intake and
use of supplements (multivitamins or minerals) also
showed a statistically significant decrease in the odds of
developing T2D across quintiles (Ptrend = 0.006). Com-
pared with the lowest quintile of energy-adjusted zinc
those in the highest quintile had almost half the odds of
developing T2D (OR = 0.50, 95% C.I. 0.32 – 0.77).Table 3 Stepwise approach to examine zinc/iron ratio as an in
Q1 Q
Number of women 1785 17
Zinc/Iron ratio [median(min, max)] 0.69
(0.28, 0.77)
0.8
(0.77,
Number of diabetics 60 7
Odds ratio
• Age adjusted 1.00 1.2
(0.85 t
• Age & non-dietary† factors adjusted 1.00 0.9
(0.61 t
• Age, non-dietary† and dietary‡ factors adjusted 1.00 0.7
(0.50 t
• Age, non-dietary† and dietary‡ factors adjusted
plus alcohol intake and use of supplements
1.00 0.7
(0.50 t
† Non-dietary factors were BMI; smoking status; HRT; exercise group; and history of
‡ Dietary factors were energy-adjusted fiber, iron and fat.The association between the energy-adjusted zinc/iron
ratio and odds of developing T2D (Table 3) followed a
similar trend to the association observed between total
energy-adjusted zinc intake and T2D. After adjusting
for age and non-dietary factors a borderline statistically
significant association was observed between energy-
adjusted zinc to iron ratio and the odds of developing
T2D (Ptrend = 0.073), however there was a consistent de-
crease in the odds of developing T2D across the quin-
tiles. A statistically significant decrease in the odds of
developing T2D across quintiles of energy-adjusted zinc
to iron ratio was observed with further adjustment fordependent predictor of a new diagnosis of diabetes
Quintile of zinc to iron ratio
2 Q3 Q4 Q5 P
84 1784 1784 1784
4
0.90)
0.95
(0.90, 1.00)
1.06
(1.00, 1.12)
1.21
(1.12, 1.75)
2 71 65 65
1
o 1.71)
1.19
(0.84 to 1.70)
1.09
(0.76 to 1.56)
1.09
(0.76 to 1.56)
0.885
1
o 1.33)
0.91
(0.62 to 1.34)
0.73
(0.49 to 1.09)
0.74
(0.50 to 1.10)
0.073
6
o 1.16)
0.71
(0.46 to 1.11)
0.54
(0.33 to 0.86)
0.50
(0.30 to 0.83)
0.003
5
o 1.14)
0.72
(0.46 to 1.12)
0.54
(0.34 to 0.87)
0.50
(0.30 to 0.83)
0.004
arthritis, CHD, hypertension, asthma and depression.
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intake and use of supplements (p = 0.004). Compared
with the lowest quintile of energy-adjusted zinc to iron
ratio those in the highest quintile had half the odds of
developing T2D (OR = 0.50, 95% C.I 0.30-0.83).
Discussion
In this longitudinal study we observed an inverse asso-
ciation between dietary zinc intake and risk of T2D in a
mid-aged female population after adjusting for potential
dietary and non-dietary confounders. In addition, we
also observed a consistent inverse association between
dietary zinc/iron ratio and risk of T2D. This suggests
that the proportion of zinc intake in relation to iron is
an important determinant of T2D risk. This makes sense
given that iron competes with zinc for binding ligands
within the intestinal lumen or for transport proteins on
the brush border of enterocytes [19]. These findings are
consistent with a recent study of 82,297 women (mostly
white nurses) aged 30 to 60 years reported by Sun et al.
[11], but this is in contrast to the findings of a study
conducted by Shi et al [12] in China of 1056 healthy
men and women aged 20 years and above. As our study is
a representative sample of mid-age, community-dwelling
women from across Australia rather than a clinical sample
it has high external validity.
Zinc is required for various aspects of cellular homeo-
stasis. It is involved in the catalytic activity of appro-
ximately 300 enzymes and plays a role in immune
function, cell division, protein and DNA synthesis and
apoptosis [2,20]. The human body has no specialised zinc
storage system [20] and so humans rely on a daily intake
of dietary zinc to maintain health and prevent disease. It is
well established that zinc has an insulin-like effect on all
insulin sensitive tissues. Insulin exerts its effect by binding
the insulin receptor and activating an intracellular signal-
ling cascade mediated by the phosphoinositide 3’-kinase
(PI3K)/Akt complex. Zinc (II) ions have been shown to
activate this same complex in numerous human cell types
[21]. Zinc (II) ions have also been shown to suppress pro-
tein tyrosine phosphatases associated with the insulin
signalling cascade thus activating the insulin signalling
cascade resulting in glucose uptake, increased glycogen
synthesis, and decreased gluconeogenesis [21].
The importance of zinc in the euglycaemic state is
highlighted by a number of animal studies that have de-
monstrated that zinc improves hyperglycaemia, glucose
intolerance, and insulin resistance [22-24]. A number of
molecular and cellular studies have shown that zinc in-
hibits lipolysis in adipocytes and stimulates glucose uptake
in rat and murine adipocytes [24,25]. Further studies have
shown that gluconeogenesis was attenuated in rat hepato-
cytes exposed to zinc and in rat renal cortex slices cul-
tured in the presence of zinc, while glycogen synthesis wasstimulated in various cell types exposed to zinc. Moreover,
zinc attenuates the high insulin secretory response to glu-
cose in isolated pancreatic islet cell [26]. Considering that
zinc is required for the synthesis and release of insulin
from pancreatic β cells [27] it follows that low levels of
bioavailable zinc may have a significant impact on glucose
metabolism and ultimately the risk of T2D.
Studies have documented zinc deficiency in most
patients with T2D leading to speculation that zinc may
have beneficial effects when administered to diabetic
patients [2,7], although the zinc loss may simply reflect
increased urinary loss due to diabetic nephropathy.
Epidemiological studies have observed that hyperzincuria
and hypozincemia are commonly seen in T2D although
the mechanism for the urinary loss has not been fully
identified [4,5]. Costarelli et al [28] found that subjects
with a lower dietary zinc intake display general impair-
ment of their zinc status, an altered lipid profile and
increased insulin production in comparison to obese sub-
jects with normal zinc dietary intake. As mentioned above
few studies have examined the effect of zinc supplementa-
tion in T2D patients with some showing an improvement
in glycaemic control. A recent study [29] showed that
supplementation either with zinc plus multi vitamin and
mineral (MVM) or MVM alone in 96 patients with T2D
resulted in a significant favourable effect on blood glucose
parameters. This beneficial effect of the zinc and MVM
supplements was dependent on the initial fasting blood
sugar, indicating that zinc was more effective earlier in the
diabetic spectrum and less effective once diabetes was
established. A more recent systematic review and meta-
analysis of 25 articles, which included 22 studies on T2D,
concluded that zinc supplementation has beneficial effects
on glycaemic control [30]. The review however had
several limitations including differences in zinc doses,
sample size, study duration, limited availability of data on
zinc intake and variation in baseline parameters and so
the conclusions remain in doubt. Despite all this study
supporting the effect of zinc in glycaemic control in T2D,
there are equally many studies that have found that zinc
supplementation have no effect on glycaemic parameters
such as Hb1Ac and glucose levels [31-33]. Another study
also did not find differences in glycaemic control among
patients with T2D treated with oral zinc compare to
placebo despite improving zinc status [34]. Hence, despite
the positive effects of supplemental zinc observed in
animals and cellular studies the connection between
dietary zinc supplementation and its role in cellular sig-
nalling in humans remains unclear and requires further
investigation.
The main strengths of this study are the prospective
design, where dietary assessment preceded the develop-
ment of T2D, and the generalizability, this being a
population-based cohort rather than a clinic sample.
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reduces selection bias and potential recall bias. The
large sample size also means that it is possible to obtain
reasonably stable estimates of incidence rates between
successive surveys.
Despite the good generalizability of this study there are
some limitations. Though the Pearson correlation coef-
ficient for dietary zinc intake was deemed acceptable
because other studies have provided a similar estimate it is
still below that observed using other dietary intake
methods such as a weighted food record. This is one of
the known limitations of using a FFQ to collect dietary
information (especially micronutrients) and is due to the
lack of homogeneity in food composition tables [35] and
over or under reporting of certain foods/food groups.
However, the use of FFQs to collect dietary information in
large population-based samples is the most cost-effective
and feasible method available and the interpretation of
findings using an FFQ study needs to consider this limita-
tion. In this study the use of an FFQ to estimate dietary
zinc intake will have underestimated the amount of zinc
consumed by study participants and biased the effect size
towards the null.
Another concern is that the existence of additional
environment sources of zinc that may have contributed
to the overall intake of zinc. However given the random
sample of subjects selected for this investigation this
additional exposure is unlikely to have affected some quin-
tiles of zinc intake more than others. Hence, the amount
of zinc consumed by all study participants is likely to be
an underestimate and this will bias the observed asso-
ciation between dietary zinc and T2D towards the null.
Given that an FFQ was used to estimate dietary zinc
intake and that there may by some environmental sources
of zinc consumption the true estimate of the association
will actually be larger than that observed in this study.
There is also the possibility that other confounding vari-
ables may not have been controlled for in the analysis and
this suggests that our estimate of the effect of zinc on
T2D risk may be subject to some residual confounding;
however given that the most important dietary (including
multivitamin use) and non-dietary confounders have been
controlled for this residual confounding is likely to be
small.
A further limitation is that dietary assessment was car-
ried out at one time only in survey 3. However, the dietary
habits of the participants are unlikely to have changed
significantly over the 6-year period from survey 3 to sur-
vey 5, as they are mid-aged and dietary patterns are likely
to remain stable. Instead of excluding participants who
develop comorbidities during the follow-up period we
controlled for these in the analysis. This was done to
account for any change in dietary habit that may have oc-
curred following the development of comorbid conditions.Although adjustments were made for all known potential
confounders, residual confounding cannot be entirely
excluded.
This study also considered the use of supplementary
zinc as and additional source and though the quantity of
zinc in the supplements was not known, analysis showed
that the proportion of people taking supplements were
not significantly different between quintiles of zinc intake.
Although multiple dietary assessments are useful to
reduce random measurement error, given that single diet-
ary assessment is likely to bias results toward the null the
fact that we still observed a significant association is an
indication that the association between dietary zinc and
dietary zinc to iron ratio is likely to be robust and even
stronger than that observed in this study.
Although T2D was self-reported we do not consider
this a significant limitation as the kappa statistic for agree-
ment between self-report of diabetes and New South
Wales Admitted Patient Data Collection (APDC) hospital
records in the mid-aged cohort was 0.75 while the pre-
valence adjusted figure is 0.93 (unpublished data).
Conclusions
In conclusion, the current study confirms the recent fin-
dings by Sun et al [11] that higher total dietary zinc intake
and high zinc/iron ratio is associated with lower risk of
T2D in women. Future research should examine this asso-
ciation in both men and women across different age
groups. A positive finding in future studies should prompt
further research to determine if zinc supplementation may
reduce the risk of developing T2D.
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